Rivaroxaban API Market Report – Research, Industry Analysis Reports and Market Demands

Global Rivaroxaban API Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global Rivaroxaban API Consumption Value by Type: 2020 Versus 2024 Versus 2031
- 1.3.2 Purity≥98%
- 1.3.3 Purity<98%
1.4 Market Analysis by Application
- 1.4.1 Overview: Global Rivaroxaban API Consumption Value by Application: 2020 Versus 2024 Versus 2031
- 1.4.2 Rivaroxaban Tablets
- 1.4.3 Others
1.5 Global Rivaroxaban API Market Size & Forecast
- 1.5.1 Global Rivaroxaban API Consumption Value (2020 & 2024 & 2031)
- 1.5.2 Global Rivaroxaban API Sales Quantity (2020-2031)
- 1.5.3 Global Rivaroxaban API Average Price (2020-2031)

2 Manufacturers Profiles

3 Competitive Environment: Rivaroxaban API by Manufacturer

3.1 Global Rivaroxaban API Sales Quantity by Manufacturer (2020-2025)
3.2 Global Rivaroxaban API Revenue by Manufacturer (2020-2025)
3.3 Global Rivaroxaban API Average Price by Manufacturer (2020-2025)
3.4 Market Share Analysis (2024)
- 3.4.1 Producer Shipments of Rivaroxaban API by Manufacturer Revenue ($MM) and Market Share (%): 2024
- 3.4.2 Top 3 Rivaroxaban API Manufacturer Market Share in 2024
- 3.4.3 Top 6 Rivaroxaban API Manufacturer Market Share in 2024
3.5 Rivaroxaban API Market: Overall Company Footprint Analysis
- 3.5.1 Rivaroxaban API Market: Region Footprint
- 3.5.2 Rivaroxaban API Market: Company Product Type Footprint
- 3.5.3 Rivaroxaban API Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global Rivaroxaban API Market Size by Region
- 4.1.1 Global Rivaroxaban API Sales Quantity by Region (2020-2031)
- 4.1.2 Global Rivaroxaban API Consumption Value by Region (2020-2031)
- 4.1.3 Global Rivaroxaban API Average Price by Region (2020-2031)
4.2 North America Rivaroxaban API Consumption Value (2020-2031)
4.3 Europe Rivaroxaban API Consumption Value (2020-2031)
4.4 Asia-Pacific Rivaroxaban API Consumption Value (2020-2031)
4.5 South America Rivaroxaban API Consumption Value (2020-2031)
4.6 Middle East & Africa Rivaroxaban API Consumption Value (2020-2031)

5 Market Segment by Type

5.1 Global Rivaroxaban API Sales Quantity by Type (2020-2031)
5.2 Global Rivaroxaban API Consumption Value by Type (2020-2031)
5.3 Global Rivaroxaban API Average Price by Type (2020-2031)

6 Market Segment by Application

6.1 Global Rivaroxaban API Sales Quantity by Application (2020-2031)
6.2 Global Rivaroxaban API Consumption Value by Application (2020-2031)
6.3 Global Rivaroxaban API Average Price by Application (2020-2031)

7 North America

7.1 North America Rivaroxaban API Sales Quantity by Type (2020-2031)
7.2 North America Rivaroxaban API Sales Quantity by Application (2020-2031)
7.3 North America Rivaroxaban API Market Size by Country
- 7.3.1 North America Rivaroxaban API Sales Quantity by Country (2020-2031)
- 7.3.2 North America Rivaroxaban API Consumption Value by Country (2020-2031)
- 7.3.3 United States Market Size and Forecast (2020-2031)
- 7.3.4 Canada Market Size and Forecast (2020-2031)
- 7.3.5 Mexico Market Size and Forecast (2020-2031)

8 Europe

8.1 Europe Rivaroxaban API Sales Quantity by Type (2020-2031)
8.2 Europe Rivaroxaban API Sales Quantity by Application (2020-2031)
8.3 Europe Rivaroxaban API Market Size by Country
- 8.3.1 Europe Rivaroxaban API Sales Quantity by Country (2020-2031)
- 8.3.2 Europe Rivaroxaban API Consumption Value by Country (2020-2031)
- 8.3.3 Germany Market Size and Forecast (2020-2031)
- 8.3.4 France Market Size and Forecast (2020-2031)
- 8.3.5 United Kingdom Market Size and Forecast (2020-2031)
- 8.3.6 Russia Market Size and Forecast (2020-2031)
- 8.3.7 Italy Market Size and Forecast (2020-2031)

9 Asia-Pacific

9.1 Asia-Pacific Rivaroxaban API Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Rivaroxaban API Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Rivaroxaban API Market Size by Region
- 9.3.1 Asia-Pacific Rivaroxaban API Sales Quantity by Region (2020-2031)
- 9.3.2 Asia-Pacific Rivaroxaban API Consumption Value by Region (2020-2031)
- 9.3.3 China Market Size and Forecast (2020-2031)
- 9.3.4 Japan Market Size and Forecast (2020-2031)
- 9.3.5 South Korea Market Size and Forecast (2020-2031)
- 9.3.6 India Market Size and Forecast (2020-2031)
- 9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
- 9.3.8 Australia Market Size and Forecast (2020-2031)

10 South America

10.1 South America Rivaroxaban API Sales Quantity by Type (2020-2031)
10.2 South America Rivaroxaban API Sales Quantity by Application (2020-2031)
10.3 South America Rivaroxaban API Market Size by Country
- 10.3.1 South America Rivaroxaban API Sales Quantity by Country (2020-2031)
- 10.3.2 South America Rivaroxaban API Consumption Value by Country (2020-2031)
- 10.3.3 Brazil Market Size and Forecast (2020-2031)
- 10.3.4 Argentina Market Size and Forecast (2020-2031)

11 Middle East & Africa

11.1 Middle East & Africa Rivaroxaban API Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Rivaroxaban API Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Rivaroxaban API Market Size by Country
- 11.3.1 Middle East & Africa Rivaroxaban API Sales Quantity by Country (2020-2031)
- 11.3.2 Middle East & Africa Rivaroxaban API Consumption Value by Country (2020-2031)
- 11.3.3 Turkey Market Size and Forecast (2020-2031)
- 11.3.4 Egypt Market Size and Forecast (2020-2031)
- 11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
- 11.3.6 South Africa Market Size and Forecast (2020-2031)

12 Market Dynamics

12.1 Rivaroxaban API Market Drivers
12.2 Rivaroxaban API Market Restraints
12.3 Rivaroxaban API Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of Rivaroxaban API and Key Manufacturers
13.2 Manufacturing Costs Percentage of Rivaroxaban API
13.3 Rivaroxaban API Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 Rivaroxaban API Typical Distributors
14.3 Rivaroxaban API Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Rivaroxaban API market size was valued at US$ 9485 million in 2024 and is forecast to a readjusted size of USD 16170 million by 2031 with a CAGR of 8.0% during review period.
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
Rivaroxaban belongs to the class of antithrombotic agents. Rivaroxaban reduces a risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack. It is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Rivaroxaban API market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Rivaroxaban API market size and forecasts, in consumption value ($ Million), sales quantity (Kg), and average selling prices (US$/Kg), 2020-2031
Global Rivaroxaban API market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Kg), and average selling prices (US$/Kg), 2020-2031
Global Rivaroxaban API market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Kg), and average selling prices (US$/Kg), 2020-2031
Global Rivaroxaban API market shares of main players, shipments in revenue ($ Million), sales quantity (Kg), and ASP (US$/Kg), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Rivaroxaban API
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Rivaroxaban API market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Dr. Reddy's Laboratories, Actis Generics Pvt Ltd., ZCL Chemicals Limited, Medichem S.A, UQUIFA, Inke, Teva Pharmaceutical Industries Ltd., Zhejiang Huahai Pharmaceutial. Co., Ltd., Morepen Labs, Shaanxi Hanjiang Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Rivaroxaban API market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Purity≥98%
Purity<98%
Market segment by Application
Rivaroxaban Tablets
Others
Major players covered
Dr. Reddy's Laboratories
Actis Generics Pvt Ltd.
ZCL Chemicals Limited
Medichem S.A
UQUIFA
Inke
Teva Pharmaceutical Industries Ltd.
Zhejiang Huahai Pharmaceutial. Co., Ltd.
Morepen Labs
Shaanxi Hanjiang Pharmaceutical
Jiangsu Jiayi
Shanghai Haoyuan
Nanjing Hicin
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Rivaroxaban API product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Rivaroxaban API, with price, sales quantity, revenue, and global market share of Rivaroxaban API from 2020 to 2025.
Chapter 3, the Rivaroxaban API competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Rivaroxaban API breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Rivaroxaban API market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Rivaroxaban API.
Chapter 14 and 15, to describe Rivaroxaban API sales channel, distributors, customers, research findings and conclusion.

Buy now